Not all HER2+ BC patients clinically benefit from trastuzumab treatment owing to intrinsic or acquired resistance [10], which depends on persistence of HER2 activation, associated with other EGFR members compensatory activations, or structural aberrations of HER2 protein altering trastuzumab binding, activation/inactivation of members of PI3K/AKT downstream to HER2, or activation of different tyrosine-kinases receptors [11,12,13,14,15]. Here, ERBB2 is linked to breast cancer.